GOLD 2026: COPD
International GOLD Current
Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2026 Report (summarised from the Pocket Guide)
Global Initiative for Chronic Obstructive Lung Disease. 2026 Report and Pocket Guide
Summary checked against the source: 2026-11
Summarised from the GOLD 2026 Pocket Guide, which condenses the full 2026 report. Page numbers are the pocket guide's printed pages.
At a glance
- Diagnosis needs spirometry: post-bronchodilator FEV1/FVC <0.7 in the right clinical context. Pre-bronchodilator spirometry can rule COPD out. [p. 3, 8]
- Severity of obstruction (GOLD 1–4) by FEV1, and ABE groups by symptoms (mMRC, CAAT) and exacerbations decide treatment. [p. 17–19]
- Initial treatment: group A a bronchodilator; groups B and E: LABA + LAMA; consider triple therapy in E if eosinophils ≥300. [Figure 3.8 · p. 27]
- Follow-up is driven by persistent dyspnoea or exacerbations, with eosinophils guiding ICS. [Figure 3.9 · p. 28]
- Exacerbations: SABA ± SAMA, prednisolone for up to 5 days, antibiotics for 5 days if indicated; NIV for respiratory acidosis (PaCO₂ ≥45, pH ≤7.35). [p. 41, 47]
- LTOT only for severe resting hypoxaemia: PaO₂ ≤55 mm Hg (or <60 with cor pulmonale or polycythaemia). [p. 21]
- Pulmonary rehabilitation benefits all grades; stop smoking; vaccinate (influenza, pneumococcal, RSV, COVID-19, Tdap, zoster). [p. 21]
Definition and diagnosis
COPD is a heterogeneous lung condition with chronic respiratory symptoms (dyspnoea, cough, sputum, exacerbations) caused by abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive airflow obstruction. It results from gene–environment interactions over a lifetime (GETomics): smoking, household and outdoor air pollution, abnormal lung development and accelerated lung ageing. Precursor states include pre-COPD and PRISm (preserved ratio impaired spirometry). [p. 3]
Severity of airflow obstruction
| Grade | Post-bronchodilator FEV1 (with FEV1/FVC <0.7) |
|---|---|
| GOLD 1, mild | ≥80% predicted |
| GOLD 2, moderate | 50–79% |
| GOLD 3, severe | 30–49% |
| GOLD 4, very severe | <30% |
Adapted from GOLD 2026 Figure 2.10 [p. 17]
Symptoms and the ABE tool
| mMRC grade | Breathless… |
|---|---|
| 0 | Only with strenuous exercise |
| 1 | Hurrying on the level or walking up a slight hill |
| 2 | Walks slower than peers, or stops for breath at own pace on the level |
| 3 | Stops after about 100 m or a few minutes on the level |
| 4 | Too breathless to leave the house, or when dressing |
Adapted from GOLD 2026 Figure 2.11 [p. 17]
The CAT has been renamed the Chronic Airways Assessment Test (CAAT): 8 items scored 0–5 (cough, phlegm, chest tightness, breathlessness on stairs, home activities, confidence leaving home, sleep, energy), total 0–40. [Figure 2.12 · p. 18]
| mMRC 0–1, CAAT <10 | mMRC ≥2, CAAT ≥10 | |
|---|---|---|
| ≥1 moderate or severe exacerbation in the previous year | Group E | Group E |
| No moderate or severe exacerbation | Group A | Group B |
GOLD 2026 lowers the threshold for group E to one moderate or severe exacerbation (earlier editions used two moderate, or one leading to admission).
Adapted from GOLD 2026 ABE assessment tool (Figure 2.13) [p. 19]
Stable COPD: drug treatment
flowchart TD
I["Initial treatment, maintenance-naive"] --> E["Group E<br/>LABA + LAMA<br/>consider LABA + LAMA + ICS if eos ≥300"]
I --> A["Group A<br/>a bronchodilator"]
I --> B["Group B<br/>LABA + LAMA"]
Adapted from GOLD 2026 Figure 3.8 [p. 27]. A single inhaler is preferred for combinations.
Follow-up: continue current treatment unless dyspnoea or exacerbations need optimising. [Figure 3.9 · p. 28]
flowchart TD
A["LABA or LAMA"] --> B["LABA + LAMA"]
B --> C["Consider changing device or molecule<br/>Add or escalate non-drug treatment<br/>Consider adding ensifentrine<br/>Look for (and treat) other causes of dyspnoea"]
flowchart TD
A["LABA or LAMA"] -->|"eos <300"| B["LABA + LAMA"]
A -->|"eos ≥300"| C["LABA + LAMA + ICS"]
B -->|"eos ≥100"| C
B -->|"eos <100"| R["Roflumilast<br/>if FEV1 <50% and chronic bronchitis"]
B -->|"eos <100"| Z["Azithromycin<br/>preferably in former smokers"]
C --> R
C --> Z
C -->|"2 moderate or 1 severe exacerbation<br/>AND eos ≥300"| BIO["Biologic:<br/>dupilumab (if chronic bronchitis)<br/>mepolizumab"]
Adapted from GOLD 2026 Figure 3.9 [p. 28]. Eosinophils in cells/µL.
When to add ICS
| Factors (despite long-acting bronchodilators) | |
|---|---|
| Strongly favours ICS | Hospitalisation for an exacerbation; ≥2 moderate exacerbations a year; eosinophils ≥300/µL; history of or concomitant asthma |
| Favours ICS | 1 moderate exacerbation a year; eosinophils 100–<300/µL |
| Against ICS | Repeated pneumonia; eosinophils <100/µL; history of mycobacterial infection |
Adapted from GOLD 2026 Figure 3.10 [p. 29]
- Already on LABA + ICS: no exacerbations and good previous response: continue if symptoms are low, escalate to triple if high. No relevant exacerbation history: consider switching to LABA + LAMA. Current exacerbations: triple therapy if eosinophils ≥100, consider LABA + LAMA if <100. [Figure 3.12 · p. 31]
- Check inhaler technique and adherence at every visit. [p. 21]
- De-escalate ICS for pneumonia or other important side effects; de-escalation with eosinophils ≥300 is more likely to bring exacerbations back. [p. 28]
Non-drug treatment
- Smoking cessation: counselling plus nicotine replacement or drugs; no evidence for e-cigarettes as a quitting aid. [p. 21]
- Vaccines: influenza, pneumococcal, RSV, COVID-19, Tdap if not given in adolescence, zoster. [p. 21]
- Pulmonary rehabilitation improves exercise capacity, symptoms and quality of life at every grade. [p. 21]
- LTOT improves survival only with severe resting hypoxaemia: PaO₂ ≤55 mm Hg, or <60 mm Hg with cor pulmonale or polycythaemia; not for moderate desaturation. [p. 21]
- Long-term NIV for marked daytime hypercapnia, especially after a recent admission. [p. 21]
- Lung volume reduction (surgical or bronchoscopic) in selected advanced emphysema. [p. 21]
Exacerbations
An exacerbation is worsening dyspnoea and/or cough and sputum over up to 14 days, often with tachypnoea and tachycardia. Look for mimics: pneumonia, pulmonary embolism, acute heart failure, pneumothorax. [p. 41]
| Severity (Rome proposal) | Features |
|---|---|
| Mild (default) | Dyspnoea VAS <5, RR <24, HR <95, SaO₂ ≥92% on usual oxygen (fall ≤3%), CRP <10 mg/L |
| Moderate (≥3 of 5) | VAS ≥5, RR ≥24, HR ≥95, SaO₂ <92% (or fall >3%), CRP ≥10; ABG may show PaO₂ 70–80 mm Hg |
| Severe | As moderate, plus PaO₂ ≤60 mm Hg and/or PaCO₂ >45 mm Hg with pH <7.35 |
Adapted from GOLD 2026 Figure 4.2 [p. 43]
Treatment [p. 41]
- SABA ± short-acting antimuscarinic as first bronchodilators.
- Systemic corticosteroid for up to 5 days in moderate or severe exacerbations.
- Antibiotics for 5 days with purulent sputum or previous lung infections.
- No methylxanthines (side effects).
- Start long-acting bronchodilators as soon as possible; at discharge, add ICS to dual bronchodilators after ≥1 moderate or severe exacerbation with raised eosinophils.
- Recovery can take 4–6 weeks.
| Support | Indications (at least one) |
|---|---|
| High-flow nasal oxygen | Persistent hypoxaemia; can't tolerate NIV or it's contraindicated; weaning from NIV; preventing reintubation |
| NIV | Respiratory acidosis: PaCO₂ ≥6.0 kPa (45 mm Hg) and pH ≤7.35; severe dyspnoea with fatigue (accessory muscles, paradoxical abdomen, recession); persistent hypoxaemia despite oxygen |
| Invasive ventilation | Life-threatening hypoxaemia despite HFNT or NIV; NIV failure or intolerance; after arrest; reduced consciousness or uncontrolled agitation; massive aspiration or vomiting; can't clear secretions; haemodynamic instability; severe arrhythmias |
Adapted from GOLD 2026 Figures 4.7–4.9 [p. 47]
Clinical pearls
- FEV1/FVC <0.7 after bronchodilator confirms COPD; FEV1 grades severity.
- Group E = ≥1 moderate or severe exacerbation in the past year (2026).
- ICS by eosinophils: ≥300 strongly favours, <100 argues against.
- Roflumilast: FEV1 <50% with chronic bronchitis. Azithromycin: former smokers.
- Exacerbation: systemic steroid up to 5 days, antibiotics × 5 days, NIV at pH ≤7.35 with PaCO₂ ≥45.
- Admit for respiratory failure, failure of initial treatment, serious comorbidity or poor home support; ICU for worsening gas exchange, confusion, need for intubation or haemodynamic instability.
Classes and levels of evidence
How GOLD 2026 grades its recommendations. Adapted from GOLD 2026 Figure A [full report]. Hover over any class or level cited on this page to see what it means.
| Evidence category | Meaning |
|---|---|
| A | RCTs and meta-analyses with a rich body of high-quality evidence and no significant limitation or bias |
| B | RCTs and meta-analyses with important limitations, or a limited body of evidence |
| C | Non-randomised trials or observational studies |
| D | Panel consensus judgement, where evidence is insufficient for a higher category |
GOLD is a strategy report rather than a graded guideline. The full report tags key statements with an evidence category from A to D; the pocket guide summarised here mostly doesn't, so citations on this page give the pocket-guide page.